TB-500

Thymosin Beta-4 (and its active fragment TB-500) is one of the most abundant intracellular peptides in the human body. It sequesters actin monomers, regulates cytoskeletal dynamics, and plays a central role in tissue repair, wound healing, and inflammation resolution. In cancer care it is used to accelerate surgical wound healing, repair radiation-damaged tissue, and reduce treatment-associated inflammation.

Properties

Sequesters G-actin (monomeric actin), promoting controlled cell migration and new vessel formation at wound sites. Activates stem/progenitor cells, particularly cardiac and neural stem cells. Downregulates pro-inflammatory cytokines (TNF-α, IL-1β). Promotes myosin expression and muscle repair. Also cross-talks with PI3K/AKT promoting cell survival in damaged tissue.

Cancer-specific applications: (1) Accelerating surgical wound and anastomosis healing post-tumour resection. (2) Reducing radiation fibrosis and radiation-induced tissue damage. (3) Peripheral neuropathy repair after platinum-based or taxane chemotherapy. (4) Managing post-treatment inflammation and tissue remodelling. IMPORTANT: Tβ4 also promotes angiogenesis — a theoretical concern in active cancer similar to BPC-157. Use during active disease requires oncologist input.

Links open on PubMed (National Library of Medicine). Research is ongoing — results may not reflect clinical use.

• Promotes angiogenesis — discuss with oncologist if using during active solid tumour treatment
• No completed human clinical trials for oncology applications
• Research compound; not approved by FDA or EMA
• May worsen oedema initially before resolution
• Storage sensitive — keep refrigerated and avoid freeze-thaw cycles